Status:

COMPLETED

Agaricus Bisporus and Influenza Vaccination Response

Lead Sponsor:

Maastricht University Medical Center

Collaborating Sponsors:

Scelta Mycofriends B.V.

CNC Grondstoffen B.V.

Conditions:

Immune Response

Eligibility:

All Genders

59+ years

Phase:

NA

Brief Summary

There are numerous in vitro and animal studies that suggested that mushrooms beneficially influence the immune system. We have recently shown that a wild isolate of the edible Agaricus bisporus mushro...

Eligibility Criteria

Inclusion

  • Aged 60 years or older during influenza season 2023/2024 (in line with RIVM guidelines)
  • BMI between 20 and 35 kg/m2
  • Willing to abstain from mushrooms other than the capsules containing a mushroom powder as provided by us during the study period.
  • Willing to keep the intake of fish oil, Zinc, Selenium and (vitamin) supplements constant
  • Willing to abstain from products / supplements enriched with Vitamin D
  • Willing to abstain from products / supplements enriched with plant sterols or stanols
  • Willing to abstain from products / supplements enriched with (β)glucans or fungi.
  • Willing to abstain from products / supplements that are mentioned to "boost your immune system"
  • Willing to abstain from (products enriched in) pre/pro-biotics
  • Willing to abstain from products/supplements enriched with ergothioneine

Exclusion

  • Already received influenza vaccination in 2023
  • Allergy to mushrooms
  • Known allergic reaction to an active component or other components of the vaccine (e.g. Chicken Eggs)
  • Having donated blood within one month prior to the start of the study, or planning to donate blood during the study
  • Excessive alcohol use (\>20 consumptions per week)
  • Regular use of soft and/or hard drugs
  • Using medication for diseases known to affect inflammation/immunity (e.g. inhaled corticosteroids and prednisone)

Key Trial Info

Start Date :

September 14 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 30 2024

Estimated Enrollment :

88 Patients enrolled

Trial Details

Trial ID

NCT06041867

Start Date

September 14 2023

End Date

May 30 2024

Last Update

March 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maastricht University Medical Center

Maastricht, Limburg, Netherlands, 6229 ER

Agaricus Bisporus and Influenza Vaccination Response | DecenTrialz